GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.265 $0.480 Thursday, 18th Apr 2024 WINT stock ended at $0.340. This is 15.30% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 50.72% from a day low at $0.265 to a day high of $0.400.
90 days $0.265 $0.532
52 weeks $0.265 $2.50

Historical Windtree Therapeutics Inc prices

Date Open High Low Close Volume
2024-02-06 $0.371 $0.380 $0.355 $0.360 258 750
2024-02-05 $0.388 $0.395 $0.365 $0.369 217 909
2024-02-02 $0.410 $0.415 $0.384 $0.400 325 836
2024-02-01 $0.438 $0.438 $0.370 $0.410 201 998
2024-01-31 $0.450 $0.450 $0.417 $0.420 433 130
2024-01-30 $0.450 $0.452 $0.430 $0.450 251 865
2024-01-29 $0.417 $0.459 $0.415 $0.458 205 363
2024-01-26 $0.450 $0.480 $0.427 $0.430 521 348
2024-01-25 $0.490 $0.522 $0.436 $0.447 1 038 433
2024-01-24 $0.450 $0.460 $0.433 $0.460 108 346
2024-01-23 $0.449 $0.485 $0.431 $0.465 169 177
2024-01-22 $0.518 $0.532 $0.476 $0.506 308 820
2024-01-19 $0.479 $0.510 $0.420 $0.502 461 302
2024-01-18 $0.525 $0.555 $0.442 $0.482 1 784 346
2024-01-17 $0.600 $0.600 $0.475 $0.484 4 412 397
2024-01-16 $0.588 $0.610 $0.565 $0.590 35 815
2024-01-12 $0.610 $0.628 $0.539 $0.572 65 623
2024-01-11 $0.655 $0.660 $0.610 $0.610 38 916
2024-01-10 $0.658 $0.658 $0.627 $0.650 53 040
2024-01-09 $0.630 $0.670 $0.630 $0.641 34 986
2024-01-08 $0.630 $0.670 $0.610 $0.650 105 218
2024-01-05 $0.603 $0.660 $0.603 $0.625 122 157
2024-01-04 $0.624 $0.627 $0.601 $0.610 112 140
2024-01-03 $0.657 $0.670 $0.600 $0.624 572 532
2024-01-02 $0.691 $0.730 $0.691 $0.698 48 204
Click to get the best stock tips daily for free!

About Windtree Therapeutics Inc

Windtree Therapeutics Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF,... WINT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT